Lebrikizumab

Last updated

Lebrikizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IL-13
Clinical data
Trade names Ebglyss
Other namesMILR1444A, RG3637, TNX-650, lebrikizumab-lbkz
AHFS/Drugs.com Ebglyss
License data
Pregnancy
category
Routes of
administration 		Subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6434H9972N1700O2034S50
Molar mass 145287.42 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). [6] [7] It is an interleukin-13 antagonist. [6] It is given by subcutaneous injection. [6]

Contents

The most common side effects include injection site reactions, dry eye and conjunctivitis (redness and discomfort in the eye) including allergic conjunctivitis. [7]

Lebrikizumab was approved for medical use in the European Union in November 2023, [7] in Canada in June 2024, [5] and in the United States in September 2024 to treat moderate-to-severe atopic dermatitis. [9] [10] [11]

Medical uses

Lebrikizumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents twelve years and older with a body weight of at least 40 kilograms (88 lb) who are candidates for systemic therapy. [7]

Mechanism of action

Lebrikizumab blocks interleukin 13 (IL-13), a cytokine (cell-signalling protein) that is produced by a type of white blood cell called Th2 cells. IL-13 is thought to induce the expression of another signalling protein, periostin, by epithelial cells of the bronchi. Periostin in turn seems to partake in a number of asthma related problems, such as bronchial hyperresponsiveness, inflammation, and activation and proliferation of airway fibroblasts, which are involved in airway remodelling. [12] [13]

This theory is supported by the fact that people with high periostin levels responded significantly better to lebrikizumab in the phase II study: the forced expiratory volume in 1 second (FEV1) was 8.2% higher than under placebo in this group (measured from the respective baselines), while low-periostin patients had 1.6% higher FEV1, and the average value for all patients was 5.5%. The FEV1 increase in low-periostin patients was not statistically significant. [14]

Society and culture

In September 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended authorizing lebrikizumab (Ebglyss) for the treatment of atopic dermatitis. [15] Lebrikizumab was authorized for medical use in the European Union in November 2023. [7]

In September 2023, the US Food and Drug Administration (FDA) declined to approve lebrikizumab due to certain findings during an inspection of a contract manufacturer, unrelated to the clinical trial data, safety, or label for lebrikizumab. [16] Lebrikizumab was approved by the FDA in September 2024. [9] [10]

Brand names

Lebrikizumab is the international nonproprietary name. [17]

Lebrikizumab is sold under the brand name Ebglyss. [7]

Research

Lebrikizumab is under investigation as an immunosuppressive medication for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. It was created by Tanox under the code name TNX-650, and a phase I clinical trial for refractory Hodgkin’s lymphoma had been performed when Genentech acquired Tanox in 2007. [18] [19] [20] It has successfully completed a phase II clinical trial for the treatment of asthma. [12]

Related Research Articles

<span class="mw-page-title-main">Dermatitis</span> Inflammatory disease of the skin

Dermatitis is a term used for different types of skin inflammation, typically characterized by itchiness, redness and a rash. In cases of short duration, there may be small blisters, while in long-term cases the skin may become thickened. The area of skin involved can vary from small to covering the entire body. Dermatitis is also called eczema but the same term is often used for the most common type of skin inflammation, atopic dermatitis.

<span class="mw-page-title-main">Pimecrolimus</span> Immunosuppressive drug

Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema).

<span class="mw-page-title-main">Omalizumab</span> Monoclonal antibody medication

Omalizumab, sold under the brand name Xolair among others, is an injectable medication to treat severe persistent allergic forms of asthma, nasal polyps, urticaria (hives), and immunoglobulin E-mediated food allergy.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Reslizumab, sold under the brand names Cinqair and Cinqaero, is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions.

Talizumab (TNX-901) is a humanized monoclonal antibody that was under development by Tanox in Houston, Texas as a new-concept therapeutic for allergic diseases. The unique anti-IgE antibody was designed to target immunoglobulin E (IgE) and IgE-expressing B lymphocytes specifically, without binding to IgE already bound by the high affinity IgE receptors on mast cells and basophils. Talizumab was tested in clinical trials at National Jewish Medical and Research Center and other medical centers and allergy clinics across the U. S. and shown to be able to prevent allergic reactions to accidental exposure to peanuts, which is contained in many kinds of foods.

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.

Ibalizumab, sold under the brand name Trogarzo, is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors.

Pitrakinra is a 15-kDa human recombinant protein of wild-type human interleukin-4 (IL-4). It is an IL-4 and IL-13 antagonist that has been studied in a phase IIb clinical trial for the treatment of asthma. Two point mutations on pitrakinra confer its ability to block signaling of IL-4 and interleukin-13 (IL-13) by preventing assembly of IL-4 receptor alpha (IL-4Rα) with either IL-2Rγ or IL-13Rα. Upregulation of Th2 cytokines, including IL-4 and IL-13, is thought to be critical for the allergic inflammation associated with atopic diseases such as asthma and eczema. The targets of pitrakinra action are inflammatory cells and structural cells that express IL-4Rα. The drug has been applied both as a subcutaneous injection and as an inhalation, but the latter formulation proved to be more effective.

Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

<span class="mw-page-title-main">Tralokinumab</span> Monoclonal antibody

Tralokinumab sold under the brand names Adtralza (EU/UK) and Adbry (US) among others, is a human monoclonal antibody used for the treatment of atopic dermatitis. Tralokinumab targets the cytokine interleukin 13.

<span class="mw-page-title-main">Dupilumab</span> Drug used to treat allergic diseases

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis, prurigo nodularis and COPD.

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis, psoriatic arthritis, and ulcerative colitis.

<span class="mw-page-title-main">Crisaborole</span> Chemical compound

Crisaborole, sold under the brand name Eucrisa among others, is a nonsteroidal topical medication used for the treatment of mild-to-moderate atopic dermatitis (eczema) in adults and children.

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.

Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23 (IL-23) and block its activity.

<span class="mw-page-title-main">Abrocitinib</span> Chemical compound

Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.

<span class="mw-page-title-main">Tirzepatide</span> Anti-diabetic and weight loss medication

Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. Tirzepatide is administered via subcutaneous injections. It is sold under the brand names Mounjaro for diabetes treatment, and Zepbound for weight loss.

References

  1. ↑ "Ebglyss (lebrikizumab)". Therapeutic Goods Administration (TGA). 23 June 2024. Retrieved 7 July 2024.
  2. ↑ "Ebglyss (Eli Lilly Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 1 July 2024. Archived from the original on 7 July 2024. Retrieved 7 July 2024.
  3. ↑ "Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Archived from the original on 10 June 2024. Retrieved 10 June 2024.
  4. ↑ "Register Of Innovative Drugs [Updated: 2024-07-04]". Health Canada . 4 July 2024. Retrieved 15 July 2024.
  5. 1 2 "Ebglyss Product information". Health Canada . 24 June 2024. Retrieved 15 July 2024.
  6. 1 2 3 4 "Ebglyss- lebrikizumab-lbkz injection, solution". DailyMed. 19 September 2024. Retrieved 5 October 2024.
  7. 1 2 3 4 5 6 7 "Ebglyss EPAR". European Medicines Agency (EMA). 21 November 2023. Archived from the original on 22 November 2023. Retrieved 22 November 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ↑ "Ebglyss Product information". Union Register of medicinal products. 17 November 2023. Archived from the original on 26 November 2023. Retrieved 11 December 2023.
  9. 1 2 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761306Orig1s000correctedltr.pdf
  10. 1 2 "FDA Approves Lilly's Ebglyss (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis" (Press release). Eli Lilly. 13 September 2024. Retrieved 17 September 2024– via PR Newswire.
  11. ↑ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 8 November 2024.
  12. 1 2 Kraft M (September 2011). "Asthma phenotypes and interleukin-13--moving closer to personalized medicine". The New England Journal of Medicine. 365 (12): 1141–4. doi:10.1056/NEJMe1108666. PMC   4390041 . PMID   21879891.
  13. ↑ "Prous Science Molecule of the Month: Lebrikizumab". Thomson Reuters. October 2011. Archived from the original on 26 October 2011. Retrieved 15 December 2011.
  14. ↑ Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. (September 2011). "Lebrikizumab treatment in adults with asthma". The New England Journal of Medicine. 365 (12): 1088–98. doi: 10.1056/NEJMoa1106469 . PMID   21812663.
  15. ↑ "Ebglyss: Pending EC decision". European Medicines Agency. 15 September 2023. Archived from the original on 20 September 2023. Retrieved 24 September 2023.
  16. ↑ "FDA Rejects Lilly's Eczema Treatment Over Third-Party Manufacturing Issues". BioSpace. 2 October 2023. Retrieved 3 October 2023.
  17. ↑ World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 63". WHO Drug Information. 24 (1). hdl: 10665/74530 .
  18. ↑ "First Patient Dosed In Phase 1 Trial Of Tanox, Inc.'s TNX-650 - News, Search Jobs, Events". Archived from the original on 3 March 2016. Retrieved 8 July 2008.
  19. ↑ "anti-IL-13 humanized monoclonal antibody TNX-650". NCI Drug Dictionary. National Cancer Institute. Archived from the original on 25 September 2009. Retrieved 10 December 2009.
  20. ↑ Clinical trial number NCT00441818 for "Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma" at ClinicalTrials.gov
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.